Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MURA

Mural Oncology plc

Sep 19 • 11:55AM ET

3.45

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • Ireland • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF VHT IWC MEDX BTEC SCHK IYY

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.35	Insider Own	7.60%	Shs Outstand	16.69M	Perf Week	9.52%
Market Cap	58.79M	Forward P/E	-	EPS next Y	-4.80	Insider Trans	-0.36%	Shs Float	15.74M	Perf Month	7.14%
Income	-173.30M	PEG	-	EPS next Q	-1.97	Inst Own	65.56%	Short Float	3.14%	Perf Quarter	6.15%
Sales	0.00M	P/S	-	EPS this Y	38.13%	Inst Trans	-	Short Ratio	3.02	Perf Half Y	-21.59%
Book/sh	12.09	P/B	0.29	EPS next Y	37.58%	ROA	-	Short Interest	0.49M	Perf Year	-
Cash/sh	12.01	P/C	0.29	EPS next 5Y	-	ROE	-	52W Range	2.88 - 17.00	Perf YTD	-41.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-82.40%	52W High	-79.71%	Beta	-
Dividend TTM	-	Quick Ratio	8.65	Sales past 5Y	6.94%	Gross Margin	-	52W Low	19.79%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	8.65	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	58.91	Volatility	5.04% 5.60%
Employees	117	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	33.02%	Payout	-	Rel Volume	0.26	Prev Close	3.45
Sales Surprise	-	EPS Surprise	4.62%	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	163.57K	Price	3.45
SMA20	6.38%	SMA50	4.83%	SMA200	-13.01%	Trades		Volume	17,276	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$15
Apr-04-24	Initiated	Morgan Stanley	Overweight	$13

Sep-10-24 07:00AM	Mural Oncology to Host First Virtual Investor Day on September 26, 2024 (GlobeNewswire)
Sep-04-24 04:30PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-24 07:00AM	Mural Oncology to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:15AM	Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress (GlobeNewswire)
Aug-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.90%
07:00AM	Loading…
Jul-31-24 07:00AM	Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors (GlobeNewswire) +5.03%
Jul-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 04:15PM	Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference (GlobeNewswire)
Jun-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.28%
May-23-24 05:00PM	Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-14-24 01:55PM	MURA Stock Earnings: Mural Oncology Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-24-24 04:00PM	Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-09-24 04:00PM	Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
04:00PM	Loading…
Apr-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.87%
Mar-26-24 01:53PM	MURA Stock Earnings: Mural Oncology Reported Results for Q4 2023 (InvestorPlace)
07:00AM	Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-24 04:35PM	Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-04-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:00AM	Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-05-24 04:30PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-24 07:00AM	Mural Oncology Announces Enhancements to Late-Stage Clinical Trials (GlobeNewswire)
Dec-18-23 11:52AM	MURA Stock Earnings: Mural Oncology Reported Results for Q3 2023 (InvestorPlace)

Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ALTSCHULLER Susan	Director	Aug 14 '24	Buy	3.21	10,000	32,071	10,000	Aug 15 04:15 PM
Keson-Brookes Maiken	See Remarks	Jul 18 '24	Sale	3.41	2,157	7,355	43,850	Jul 18 04:04 PM
Loew Caroline	Chief Executive Officer	Jul 08 '24	Sale	2.91	12,531	36,465	240,391	Jul 08 08:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MURA

Mural Oncology plc

Upgrade your FINVIZ experience